| |  Online-Ressource |
|---|
| Verfasst von: | Gierschek, Fenja [VerfasserIn]  |
|---|
| | Schlueter, Juliane [VerfasserIn] |
|---|
| | Kühnel, Ines [VerfasserIn] |
|---|
| | Feigl, Frederik Fabian [VerfasserIn] |
|---|
| | Schmiedel, Dominik [VerfasserIn] |
|---|
| | Prüfer, Maren [VerfasserIn] |
|---|
| | Buchinger, Leon [VerfasserIn] |
|---|
| | Cerwenka, Adelheid [VerfasserIn] |
|---|
| | Cappel, Claudia [VerfasserIn] |
|---|
| | Huenecke, Sabine [VerfasserIn] |
|---|
| | Köhl, Ulrike [VerfasserIn] |
|---|
| | Wels, Winfried S. [VerfasserIn] |
|---|
| | Ullrich, Evelyn [VerfasserIn] |
|---|
| Titel: | Empowering natural killer cells to combat acute myeloid leukemia |
|---|
| Titelzusatz: | perspective on CAR-NK Cell therapy |
|---|
| Verf.angabe: | Fenja Gierschek, Juliane Schlueter, Ines Kühnel, Frederik Fabian Feigl, Dominik Schmiedel, Maren Prüfer, Leon Buchinger, Adelheid Cerwenka, Claudia Cappel, Sabine Huenecke, Ulrike Köhl, Winfried S. Wels, Evelyn Ullrich, on behalf of the Translational Oncology Consortium “NKfit4AML” sponsored by the German Cancer Aid |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | October 1, 2024 |
|---|
| Umfang: | 19 S. |
|---|
| Fussnoten: | Gesehen am 07.01.2025 |
|---|
| Titel Quelle: | Enthalten in: Transfusion medicine and hemotherapy |
|---|
| Ort Quelle: | Basel : Karger, 2003 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | (2024), Seite 1-19 |
|---|
| ISSN Quelle: | 1660-3818 |
|---|
| Abstract: | Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML. Summary: Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC). Key Messages: In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future. |
|---|
| DOI: | doi:10.1159/000540962 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1159/000540962 |
|---|
| | kostenfrei: Volltext: https://karger.com/tmh/article/doi/10.1159/000540962/913830/Empowering-Natural-Killer-Cells-to-Combat-Acute |
|---|
| | DOI: https://doi.org/10.1159/000540962 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1913625591 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Empowering natural killer cells to combat acute myeloid leukemia / Gierschek, Fenja [VerfasserIn]; October 1, 2024 (Online-Ressource)
